NL-OMON48261招募中不适用
EVALUATION OF BIOMARKERS OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH TOPICAL PRESCRIPTION THERAPIES OR WHEN THOSE THERAPIES ARE NOT MEDICALLY ADVISABLE - PEDISTAD BIOMARKER STUDY
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 2 至 11（—）
入选标准
- •1. Participation in the OBS15333 pediatric AD registry
- •2. Signed informed consent by the parent/legally acceptable
- •representative and assent by the participant appropriate to the
- •participant*s age.
排除标准
- •Not applicable
研究者
相似试验
进行中（未招募）
不适用
AMBITIOUSAtopic Dermatitis Biomarker Identification Trial in Omalizumab UsageSingle- arm trial to identify potential markers underlying variability in response to Omalizumab (Xolair®) treatment in atopic dermatitis - AMBITIOUSAMBITIOUS is a trial to identify potential markers underlying variability in response to Omalizumab (Xolair®) treatment in atopic dermatitisAtopische Dermatitis is a common inflammatory skin disease showing chronically relapsing eczema and high association with elevated serum IgE levels.MedDRA version: 14.0Level: LLTClassification code 10029264Term: Neurodermatitis aggravatedSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2010-018559-84-DEMedizinische Fakultät der technischen Universität Muenchen20
已完成
不适用
Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY)Dermatitis AtopicNCT03849716Sanofi266
已完成
不适用
Biomarkers in Atopic Dermatitis and Psoriasis The Netherlandsatopic eczema10014982Atopic dermatitisNL-OMON48036Academisch Medisch Centrum110
招募中
不适用
BIOMAD NL study<p>Atopic dermatitis, atopic eczema</p>NL-OMON21253Amsterdam UMC, Academic Medical Center110
招募中
不适用
Investigating biomarkers for development of atopic dermatitis in early childhood using maternal-infant hair-related microRNAEczemaJPRN-UMIN000027834Departments of Pediatrics Juntendo University, Faculty of Medicine 3-1-3 Hongo, Bunkyo-ku TOKYO, 113-0033, JAPAN TEL +81-3-3813-3111 FAX +81-3-5800-1580500